Targeting BCR-ABL-JAK2 cooperative activities may reverse the innate TKI-resistance phenotype of CML LSCs and sensitize them to TKI. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.